Evidence map›Paper›PMID 38299453›Full record

ArticleACS chemical neuroscience2024

Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain.

Wojciech Michno, Andrew Bowman, Durga Jha, Karolina Minta, Junyue Ge, Srinivas Koutarapu, Henrik Zetterberg, Kaj Blennow, Tammaryn Lashley, Ron M A Heeren and 1 more

Open access · hybridAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Lipid Biochemistry and its Role in Human Diseases.Current medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Wojciech MichnoDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Andrew BowmanMaastricht MultiModal Molecular Imaging Institute (M4I), Maastricht University, Maastricht 6229 ER, The Netherlands.
Durga JhaDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Karolina MintaDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Junyue GeDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Srinivas KoutarapuDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.
Tammaryn LashleyDepartment of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, Queen Square, London WC1N 3BG, United Kingdom.
Ron M A HeerenMaastricht MultiModal Molecular Imaging Institute (M4I), Maastricht University, Maastricht 6229 ER, The Netherlands.ORCID 0000-0002-6533-7179
Jörg HanriederDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal 43180, Sweden.ORCID 0000-0001-6059-198X
University of Gothenburg · SEMaastricht University · NLNational Hospital for Neurology and Neurosurgery · GBScience for Life Laboratory · SEUniversity of Science and Technology of China · CNUniversity of Wisconsin–Madison · USUppsala University · SE

Funding

Understanding Amyloid Pathology - Multiomic Activity Imaging of Plaque Formation Dynamics (AmyMAP)R01AG078796 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Jeffrey Nicholas Savas · 2022 to 2026
$2.7M
Human in vivo stable isotope labeling kinetics (iSILK) to quantify brain amyloid plaque kineticsR21AG078538 · NIA · WASHINGTON UNIVERSITY · PI HANRIEDER, JORG, SCHWETYE, KATHERINE · 2022 to 2022
$411k
Insights into Amyloid Pathogenicity DynamicsR21AG080705 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HANRIEDER, JORG, SAVAS, JEFFREY NICHOLAS · 2023 to 2024
$401k
NIA NIH HHS R01 AG078796NIA NIH HHS R21 AG078538NIA NIH HHS R21 AG080705
6 · The paper itself

Abstract

Lipid dysregulations have been critically implicated in Alzheimer's disease (AD) pathology. Chemical analysis of amyloid-β (Aβ) plaque pathology in transgenic AD mouse models has demonstrated alterations in the microenvironment in the direct proximity of Aβ plaque pathology. In mouse studies, differences in lipid patterns linked to structural polymorphism among Aβ pathology, such as diffuse, immature, and mature fibrillary aggregates, have also been reported. To date, no comprehensive analysis of neuronal lipid microenvironment changes in human AD tissue has been performed. Here, for the first time, we leverage matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) through a high-speed and spatial resolution commercial time-of-light instrument, as well as a high-mass-resolution in-house-developed orbitrap system to characterize the lipid microenvironment in postmortem human brain tissue from AD patients carrying Presenilin 1 mutations (PSEN1) that lead to familial forms of AD (fAD). Interrogation of the spatially resolved MSI data on a single Aβ plaque allowed us to verify nearly 40 sphingolipid and phospholipid species from diverse subclasses being enriched and depleted, in relation to the Aβ deposits. This included monosialo-gangliosides (GM), ceramide monohexosides (HexCer), ceramide-1-phosphates (CerP), ceramide phosphoethanolamine conjugates (PE-Cer), sulfatides (ST), as well as phosphatidylinositols (PI), phosphatidylethanolamines (PE), and phosphatidic acid (PA) species (including Lyso-forms). Indeed, many of the sphingolipid species overlap with the species previously seen in transgenic AD mouse models. Interestingly, in comparison to the animal studies, we observed an increased level of localization of PE and PI species containing arachidonic acid (AA). These findings are highly relevant, demonstrating for the first time Aβ plaque pathology-related alteration in the lipid microenvironment in humans. They provide a basis for the development of potential lipid biomarkers for AD characterization and insight into human-specific molecular pathway alterations.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainCeramidesDisease Models, AnimalGas Chromatography-Mass SpectrometryHumansMiceMice, TransgenicPlaque, AmyloidSphingolipidsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCeramidesSphingolipidsAlzheimer’s diseasemass spectrometry imagingneurolipidomicsplaque pathologypresenilin 1β-amyloid

Identifiers

PMID38299453
PMCPMC10885149
OpenAlexW4391448463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.